Critical Update for Regeneron Pharmaceuticals Investors: Class Action Lawsuit Notice

Important Notice for Regeneron Pharmaceuticals, Inc. Shareholders

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent player in the biotech industry, is at the center of a class action lawsuit, with potential implications for shareholders who purchased stocks during a specified timeframe. This article outlines the key details of the case led by The Gross Law Firm, including allegations, deadlines, and next steps for affected investors.

Background of the Class Action

The Gross Law Firm has issued a formal notice highlighting the ongoing class action lawsuit concerning Regeneron Pharmaceuticals. The lawsuit pertains to allegations that during the period from November 2, 2023, to October 30, 2024, Regeneron misled investors by making false statements regarding its business practices and financial health.

Investors who purchased shares of REGN during this time are encouraged to participate in the class action, with a particular focus on securing lead plaintiff status. It is crucial for concerned shareholders to engage promptly, as the deadline for lead plaintiff registration is March 10, 2025. Moreover, registering does not obligate investors to any costs; they can follow the case's developments without financial commitment.

Allegations Overview

The lawsuit's core allegations revolve around misleading practices associated with Regeneron's pricing strategies and disclosures. Key points of contention include:

1. Undisclosed Payments - The complaint reveals that Regeneron allegedly made undisclosed payments covering credit card fees to distributors. These arrangements were made on the condition that they would not charge higher fees to patients using credit cards to purchase Eylea, one of the company’s crucial drugs.
2. Misleading Sales Boosts - The lawsuit argues that these undisclosed credit card fee payments effectively subsidized prices for Eylea, leading to artificially inflated sales figures which misled shareholders about the company’s true performance.
3. False Claims Act Violation - By not adequately reporting these fee-related price concessions, Regeneron reportedly overstated the average selling price (ASP) of Eylea, which raises serious legal concerns under the False Claims Act.
4. Impact on Shareholders - The misleading statements and omission of crucial information are alleged to have created an inflated perception of the company, ultimately affecting stock valuations and investor trust.

These issues raise significant questions regarding Regeneron’s business ethics and transparency, which investors should be wary of as they assess the situation.

Next Steps for Interested Shareholders

Affected shareholders are urged to take immediate action by registering their details through The Gross Law Firm’s portal. Once registered, investors will gain access to regular updates through a portfolio monitoring system, keeping them informed about the case's progress.

Engaging promptly is essential due to the upcoming March 10, 2025 deadline for potential lead plaintiffs, who may play a pivotal role in the proceedings.

To register, investors can follow the link provided in the notice from The Gross Law Firm, ensuring that they do not miss out on their right to participate in this significant legal action.

Why Choose The Gross Law Firm?

The Gross Law Firm is highly regarded for their commitment to protecting investors' rights and ensuring justice in cases of financial misconduct. Their experience in handling class action lawsuits positions them well to advocate for the best interests of shareholders affected by Regeneron's alleged deceptive practices.

In conclusion, this class action lawsuit presents a critical opportunity for Regeneron investors to seek recovery for potential losses incurred due to misleading information. Timely registration and active participation will be key to navigating this legal landscape effectively.

For further inquiries or detailed assistance, contact The Gross Law Firm directly at their New York office:

Contact Details
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903